Clinical trial
Evaluation of Galcanezumab in the Prevention of Chronic Migraine (REGAIN)
Evaluation of Galcanezumab in the Prevention of Chronic Migraine (REGAIN)
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.
Study Type: Interventional (Clinical Trial)
Actual Enrolment: 1113 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Actual Study Start Date: November 30, 2015
Actual Primary Completion Date: March 16, 2017
Estimated Study Completion Date: July 14, 2021
Arms:
- Experimental: Galcanezumab 120 mg
- Experimental: Galcanezumab 240 mg
- Placebo Comparator: Placebo
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Expected enrolment | 1117 |
| Study start date | 30 November 2015 |
| Actual study completion date | 14 July 2021 |